Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2018-05-31 17:13:47
Reporting Period:
Accepted Time:
2018-05-31 17:13:47
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1461993 Melinta Therapeutics Inc. W MLNT Pharmaceutical Preparations (2834) 454440364
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1582285 Mark Daniel Wechsler C/o Melinta Therapeutics, Inc.
300 George Street, Suite 301
New Haven CT 06511
See Remarks Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-05-29 50,000 $5.00 50,000 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
  1. These shares were purchased from the underwriters pursuant to an underwritten public offering by the Issuer. The offering closed on May 29, 2018.